User:Mr. Ibrahem/Risankizumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized |
| Target | interleukin 23A |
| Clinical data | |
| Pronunciation | RIS an KIZ ue mab |
| Trade names | Skyrizi |
| Other names | BI-655066, ABBV-066, risankizumab-rzaa |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a619035 |
| License data | |
| Pregnancy category |
|
| Routes of administration | Subcutaneous injection |
| Drug class | Monoclonal antibody[2] |
| Legal status | |
| Legal status | |
| Chemical and physical data | |
| Formula | C6476H9992N1720O2016S44 |
| Molar mass | 145611.84 g·mol−1 |
Risankizumab, sold under the brand name Skyrizi, is a medication used to treat moderate to severe plaque psoriasis.[2] Other uses may include generalized pustular psoriasis, erythrodermic psoriasis and psoriatic arthritis.[6]
Common side effects include upper respiratory tract infection, headache, tiredness, and pain at the site of injection.[4][5] It also increases the risk of other infections.[5] While there is no evidence of harm in pregnancy, such use has not been well studied.[7] It is a monoclonal antibody that attaches to and blocks interleukin 23A (IL-23A).[4][8]
Risankizumab was approved for medical use in the United States in 2019.[5][4] In the United States it costs about 17,800 USD per dose as of 2021.[9] In the United Kingdom this amount costs the NHS about £3,300.[10]
References[edit]
- ^ a b "Risankizumab (Skyrizi) Use During Pregnancy". Drugs.com. 15 July 2019. Archived from the original on 28 October 2020. Retrieved 23 September 2020.
- ^ a b c d "Skyrizi- risankizumab-rzaa kit". DailyMed. 12 June 2020. Archived from the original on 29 August 2021. Retrieved 23 September 2020.
- ^ "Skyrizi 75 mg solution for injection in pre-filled syringe - Summary of Product Characteristics (SmPC)". (emc). Archived from the original on 29 August 2021. Retrieved 23 September 2020.
- ^ a b c d e "Skyrizi". Archived from the original on 25 October 2020. Retrieved 18 October 2021.
- ^ a b c d "Risankizumab-rzaa Monograph for Professionals". Drugs.com. Archived from the original on 28 September 2021. Retrieved 18 October 2021.
- ^ "Japan Approves Risankizumab for Psoriasis & Psoriatic Arthritis". The Rheumatologist. 15 April 2019. Archived from the original on 24 June 2021. Retrieved 24 June 2021.
- ^ "Risankizumab (Skyrizi) Use During Pregnancy". Drugs.com. Archived from the original on 28 October 2020. Retrieved 18 October 2021.
- ^ Singh S, Kroe-Barrett RR, Canada KA, Zhu X, Sepulveda E, Wu H, et al. (July–August 2015). "Selective targeting of the IL23 pathway: Generation and characterization of a novel high-affinity humanized anti-IL23A antibody". mAbs. 7 (4): 778–91. doi:10.1080/19420862.2015.1032491. PMC 4622456. PMID 25905918.
- ^ "Skyrizi Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 30 September 2021. Retrieved 18 October 2021.
- ^ BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 1326. ISBN 978-0-85711-369-6.
{{cite book}}: CS1 maint: date format (link)